Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common stock. (4) Represents impairment charges on the Company’s long-lived assets.

The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common stock. (3) Represents acquisition and related integration costs incurred ...

Exact Sciences stock collapsed Wednesday — undercutting its 50-day and 200-day lines — after the Cologuard maker reported ...

Modeling data show Cologuard PlusTM test delivers highest life-years gained with fewest number of colonoscopies among noninvasive colorectal cancer (CRC) screening strategies “Exact Sciences is ...

“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an ... of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports ...

Exact Sciences ... performance of the Cologuard Plus test in a commercial setting. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of ...